Biotechnology News and Research

RSS

Telaprevir-based regimens increase rates of SVR in patients with genotype 1 HCV infection

In a clinical trial known as PROVE 3 published in this week's New England Journal of Medicine, treatment with telaprevir-based regimens significantly increased rates of sustained viral response (SVR) in patients with genotype 1 hepatitis C virus (HCV) infection who did not achieve SVR with at least one prior course of pegylated-interferon and ribavirin therapy.

8 Apr 2010

ADDF, AFTD announce recipients of Frontotemporal Dementia Drug Discovery Program award

The Alzheimer's Drug Discovery Foundation (ADDF) and the Association for Frontotemporal Dementias (AFTD) announced today the recipients of their third annual research award, Frontotemporal Dementia Drug Discovery Program. The goal of the program is to accelerate the development of novel therapies for frontotemporal dementia (FTD). The program will provide a total of $1,200,000 in research grants over four years.

8 Apr 2010

Phase III trial of brentuximab vedotin for post-transplant Hodgkin lymphoma initiated

Seattle Genetics, Inc., Takeda Pharmaceutical Company Limited and its wholly owned subsidiary Millennium: The Takeda Oncology Company today announced the initiation of a phase III clinical trial of brentuximab vedotin (SGN-35) for post-transplant Hodgkin lymphoma patients. Brentuximab vedotin is an antibody-drug conjugate (ADC) targeted to CD30, which is expressed on malignant Hodgkin lymphoma cells.

8 Apr 2010

Biocartis closes Series 'B' equity financing round

Biocartis SA, a biotech company active in the field of personalized medicine and focused on fast, multiplexed and fully integrated molecular diagnostics based on its proprietary micro-technology and sample preparation platforms, today announced the successful closing of a Series B equity financing round. The Company raised EUR 30 million (~ USD 41.3 million) from its current shareholder base of leading life science investors and two new strategic investors from the pharmaceutical/diagnostic industry.

From Biocartis 8 Apr 2010

Single vaccine for anthrax and plague: iBio confirms grant of rights

iBio, Inc. confirmed today the grant of rights to use iBio's proprietary technology, the iBioLaunch™ platform, in support of a $5.3 million government-funded project for the development of a single vaccine to protect against both anthrax and plague. The project will be managed by Fraunhofer USA Center for Molecular Biotechnology (CMB) pursuant to the long-term agreement between iBio and CMB for advancement of the iBio technology.

8 Apr 2010

Sigma-Aldrich, Boehringer Ingelheim Pharma enter distribution agreement for RESOMER polymers

Sigma-Aldrich® announced today it has entered into a distribution agreement with Boehringer Ingelheim Pharma GmbH & Co. KG, Germany, to offer its portfolio of RESOMER biodegradable polylactide (PLA) and poly(lactide-co-glycolide) (PLGA) polymers to the research community.

8 Apr 2010

Angiotech Pharmaceuticals acquires manufacturing, intellectual property rights from Haemacure

Angiotech Pharmaceuticals, Inc., a specialty pharmaceutical and medical device company, today announced the closing of its acquisition of certain product candidates and technology assets of Haemacure Corporation. Haemacure has been involved in proceedings under Canada's Bankruptcy and Insolvency Act and Chapter 11 of the United States Bankruptcy Code.

8 Apr 2010

Parents lack understanding of causes, signs and symptoms of dehydration in children

Dehydration is a condition that can have a significant impact on children and, if left untreated, may lead to serious complications and hospitalization. A national survey of more than 800 parents with children between the ages of one month and 10 years found that three out of five parents reported needing to know more information about dehydration, such as when to see a physician, warning signs, and treatment, if their child became sick - pointing to a greater need for awareness and education around the condition and its treatment.

From Baxter International Inc. 8 Apr 2010

Results of M118 EMINENCE clinical trial published in Circulation

Momenta Pharmaceuticals, Inc., a biotechnology company specializing in the characterization and engineering of complex mixture drugs, today announced that the results of the M118 EMINENCE clinical trial have published in Circulation.

8 Apr 2010

Atlantic-Pacific Capital raises $701M through DRI Capital managed Drug Royalty II fund

Atlantic-Pacific Capital, a leading independent global placement agent, announced today the final closing of Drug Royalty II with $701 million of equity capital commitments. The Fund, managed by DRI Capital, had an initial target of $500 million and received tremendous support from a broad group of institutional investors across the U.S., Canada, Europe, Australia and Asia. Atlantic-Pacific Capital acted as the exclusive global placement agent and advisor.

8 Apr 2010

Aushon BioSystems introduces new multiplex biomarker Human Vascular Injury Panels

Aushon BioSystems, Inc., a leading provider of advanced microarray instrumentation and laboratory services for biomarker discovery, development and analysis, announces the availability of new Human multiplex biomarker panels for the quantification of seven biomarkers related to drug-induced vascular injury.

8 Apr 2010

New studies supporting Teva Pharmaceutical Industries' CNS portfolio to be presented at AAN 2010

Teva Pharmaceutical Industries Ltd. today announced that several new studies supporting the company's innovative central nervous system portfolio will be presented at the 62nd American Academy of Neurology Annual Meeting in Toronto, April 10-17, 2010.

8 Apr 2010

FDA grants final approval for Teva Pharmaceutical Industries' generic Hyzaar and Cozaar

Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration has granted final approval for the Company's generic versions of Merck's antihypertensive agents Hyzaar® (hydrochlorothiazide; losartan potassium) and Cozaar® (losartan potassium).

8 Apr 2010

DealSearchOnline.com announces $72.3B committed to fund 291 managed care mergers and acquisitions

More than $72.3 billion was committed to fund 291 managed care mergers and acquisitions announced during the 10-year period ended December 31, 2009, according to DealSearchOnline.com. UnitedHealth Group was the acquirer in 10 of the top 25 managed care mergers and acquisitions announced during 10-year period ended December 31, 2009.

7 Apr 2010

Raptor Pharmaceutical engages The Trout Group for strategic advisory and investor relations services

Raptor Pharmaceutical Corp., today announced the engagement of The Trout Group LLC, a leading New York-based investor relations and strategic advisory firm. The Trout Group will work with Raptor to facilitate the Company's exposure to the international capital markets and coordinate their communications with investors worldwide.

7 Apr 2010

Cepheid to launch GeneXpert Infinity-48 in Europe at 20th ECCMID

Cepheid will initiate European launch of its newest addition to the GeneXpert® family of molecular diagnostic testing systems, the GeneXpert Infinity-48, at the 20th annual European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Vienna, Austria. The GeneXpert Infinity-48 System is the world's first and only fully-automated, random-access system designed for management of the entire molecular testing workflow — from sample data, cartridge loading and unloading, to final reporting of test results and disposal of cartridges.

7 Apr 2010

Illumina launches VeraCode ADME Core Panel

Illumina, Inc. today announced the launch of its VeraCode ADME Core Panel designed to help researchers study genetic predispositions for differential drug response and adverse events. The VeraCode ADME Core Panel offers the most complete representation of the key biomarkers associated with drug absorption, distribution, metabolism and excretion (ADME) as standardized by pharmaceutical industry experts in the PharmADME Core List.

From Illumina, Inc. 7 Apr 2010

Sigma-Aldrich, HSI sign distribution agreement for patented stable isotope labeled synthetic reagents

Sigma-Aldrich® announced today that it has signed an agreement with New Mexico Highlands University through its licensee, Highlands Stable Isotope Corp., to exclusively distribute a novel set of patented stable isotope labeled synthetic reagents.

7 Apr 2010

Officials of Kylin Therapeutics receive an issued patent from USPTO

Officials of Kylin Therapeutics Inc., a leading RNAi company, announced this week that they received an issued patent from the U.S. Patent and Trademark Office.

7 Apr 2010

Researchers commence Phase 2 research study to test CERE-110 for AD

Researchers at Banner Sun Health Research Institute are about to start the first Phase 2 research study to test a gene transfer agent for Alzheimer's disease. AD is a degenerative and ultimately fatal disorder affecting as many as five million Americans and that number is expected to soar to more than 11 million by 2040.

7 Apr 2010

Biotechnology News and Research

Telaprevir-based regimens increase rates of SVR in patients with genotype 1 HCV infection

ADDF, AFTD announce recipients of Frontotemporal Dementia Drug Discovery Program award

Phase III trial of brentuximab vedotin for post-transplant Hodgkin lymphoma initiated

Biocartis closes Series 'B' equity financing round

Single vaccine for anthrax and plague: iBio confirms grant of rights

Sigma-Aldrich, Boehringer Ingelheim Pharma enter distribution agreement for RESOMER polymers

Angiotech Pharmaceuticals acquires manufacturing, intellectual property rights from Haemacure

Parents lack understanding of causes, signs and symptoms of dehydration in children

Results of M118 EMINENCE clinical trial published in Circulation

Atlantic-Pacific Capital raises $701M through DRI Capital managed Drug Royalty II fund

Aushon BioSystems introduces new multiplex biomarker Human Vascular Injury Panels

New studies supporting Teva Pharmaceutical Industries' CNS portfolio to be presented at AAN 2010

FDA grants final approval for Teva Pharmaceutical Industries' generic Hyzaar and Cozaar

DealSearchOnline.com announces $72.3B committed to fund 291 managed care mergers and acquisitions

Raptor Pharmaceutical engages The Trout Group for strategic advisory and investor relations services

Cepheid to launch GeneXpert Infinity-48 in Europe at 20th ECCMID

Illumina launches VeraCode ADME Core Panel

Sigma-Aldrich, HSI sign distribution agreement for patented stable isotope labeled synthetic reagents

Officials of Kylin Therapeutics receive an issued patent from USPTO

Researchers commence Phase 2 research study to test CERE-110 for AD

Event guide: 3rd IMPACCT Real World Evidence Summit Europe eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News